Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics is a strategic step to strengthen its drug portfolio
In a significant strategic move, Bristol Myers Squibb (BMS) has announced its acquisition of Karuna Therapeutics for a staggering $14 billion in cash. This acquisition [more…]